The 6th ISCC
November 13 -14, 2001
Yurakucho Asahi Hall
November 13, 2001 (Tue)
13:00 - 13:10
Haruo Sugano (Cancer Chemotherapy Center, Tokyo)
Welcome and Introduction
I Drug development based on genome sequencing and expression profiling
Chairpersons: Ivan Horak (Pharmacia, Co., Peapack, NJ)
Yusuke Nakamura (Univ. Tokyo, Tokyo)
13:10–13:40
Susan Holbeck (NCI, Bethesda, MD)
The NCI 60 human tumor cell line panel : A tool linking molecular targets to drug sensitivity
13:40–14:10
Mark J. Ratain (Univ. Chicago, Chicago, IL)
Pharmacogenetics of anticancer agents
14:10–14:30
Hiroshi Sugiyama (Tokyo Medical and Dental Univ., Tokyo)
Sequence-specific alkylating polyamide as a tailor-made antitumor agent
14:30–14:45
Discussion
14:45–15:05
Coffee Break
II Angiogenesis Inhibitors and Antimetastatic Agents
Chairpersons: Herbert M. Pinedo (Free Univ., Netherlands)
Saburo Sone (Univ. Tokushima, Tokushima)
15:05–15:35
Raffaella Giavazzi (Mario Negri Institute, Bergamo, Italy)
Angiogenesis inhibitors in combination therapy
15:35–15:55
Kazuhiko Yonekura (Taiho Pharmaceutical, Co., Saitama)
Preclinical efficacy of TSU-16 and TSU-68
15:55–16:25
Eric Holmgren (Genentech, Inc., South San Francisco, CA)
Anti-VEGF antibody : Clinical experience in Phase II trials
16:25–16:40
Discussion
III Drugs Targeted at Specific Gene Function in Tumors (Part I)
Chairpersons: Jean P. Armand (Institut Gustave-Roussy, Villejuif, France)
Ryuzo Ueda (Nagoya City Univ., Nagoya)
16:40–17:10
Ivan Horak (Pharmacia, Co., Peapack, NJ)
Molecular targets for therapeutic intervention; Are we ready?
17:10–17:40
Ross C. Donehower (Johns Hopkins Univ., Baltimore, MD)
Alteration of gene expression as a strategy for cancer treatment
17:40–18:00
Discussion
18:00–19:00
Mixer
November 14, 2001 (Wed)
IV Drugs Targeted at Specific Gene Function in Tumors (Part II)
Chairpersons: Edward A. Sausiville (NCI, Bethesda, MD)
Yutaka Ariyoshi (Aichi Hosp., Nagoya)
10:00–10:30
Peter Elliott (Millennium Pharmaceuticals, Cambridge, MA)
Clinical development of the proteasome inhibitor, PS-341
10:30–10:50
Akihiro Tomida (Univ. Tokyo, Tokyo)
Proteasome inhibitors in cancer chemotherapy
10:50 - 11:10
Kazuhiko Nakagawa (Kinki Univ., Osaka)
Farnesyltransferase inhibitor R115777
11:10–11:30
Saburo Sone (Univ. Tokushima, Tokushima)
EGFR tyrosine kinase inhibitor ZD1839
11:30–12:00
Matthias Mueser (Merck, Darmstadt, Germany)
Treatment of cancer with cetuximab, an anti-EGFR monoclonal antibody
12:00–12:20
Nagahiro Saijo (National Cancer Center Hosp., Tokyo)
CPT-11 in the treatment of SCLC
12:20–12:35
Discussion
12:35–13:30
Lunch Break
V Cancer-induced bone diseases: Mechanism and treatment
Chairpersons: Raffaella Giavazzi (Mario Negri Institute, Bergamo, Italy)
Nagahiro Saijo (National Cancer Center Hosp., Tokyo)
13:30–14:00
Lance Liotta (NCI, Bethesda, MD)
Basic mechanism of cancer metastasis
14:00–14:30
John Shaughnessy (Donna and Donald Lambert Lab. of Myeloma, Little Rock, AK)
Global gene expression profiling in predictive therapy for multiple myeloma
14:30–15:00
Bart Barlogie (Arkansas Cancer Research Center, Little Rock, AK)
Toward curing myeloma–the Arkansas approach
15:00–15:30
Robert D. Rubens (Guys Hospital, London, UK)
Treatment of breast cancer metastasis to bone
15:30–15:45
Discussion
15:45–16:05
Coffee Break
VI Current Status in New Drug Development in Japan, Europe and the US
Chairpersons: Ross C. Donehower (Johns Hopkins Univ., Baltimore, MD)
Masahiro Fukuoka (Kinki Univ., Osaka)
16:05–16:35
Takashi Tsuruo (Univ. Tokyo, Tokyo)
International development of antitumor drugs in Japan
16:35–17:05
Jean P. Armand (Institut Gustave-Roussy, Villejuif, France)
New drugs in early development at the Institut Gustave-Roussy
17:05–17:35
Edward A. Sausiville (NCI, Bethesda, MD)
Novel molecular targets for cancer treatment under development by NCI
17:35–17:50
Discussion
Closing Remark
17:50 - 18:00
Takashi Tsuruo (Univ. Tokyo, Tokyo)
